Proof of Concept Trial of Dronabinol in Obstructive Sleep Apnea
Open Access
- 1 January 2013
- journal article
- research article
- Published by Frontiers Media SA in American Journal of Translational Research
Abstract
Study Objective: Animal data suggest that Δ9-TetraHydroCannabinol (Δ9THC) stabilizes autonomic output during sleep, reduces spontaneous sleep-disordered breathing, and blocks serotonin-induced exacerbation of sleep apnea. On this basis, we examined the safety, tolerability, and efficacy of dronabinol (Δ9THC), an exogenous Cannabinoid type 1 and type 2 (CB1 and CB2) receptor agonist in patients with Obstructive Sleep Apnea (OSA). Design and Setting: Proof of concept; single-center dose-escalation study of dronabinol. Participants: Seventeen adults with a baseline Apnea Hypopnea Index (AHI) ≥15/h. Baseline polysomnography (PSG) was performed after a 7-day washout of Continuous Positive Airway Pressure treatment. Intervention: Dronabinol was administered after baseline PSG, starting at 2.5 mg once daily. The dose was increased weekly, as tolerated, to 5 mg and finally to 10 mg once daily. Measurements and Results: Repeat PSG assessments were performed on nights 7, 14, and 21 of dronabinol treatment. Change in AHI (ΔAHI, mean ± SD) was significant from baseline to night 21 (−14.1 ± 17.5; p = 0.007). No degradation of sleep architecture or serious adverse events was noted. Conclusion: Dronabinol treatment is safe and well-tolerated in OSA patients at doses of 2.5–10 mg daily and significantly reduces AHI in the short-term. These findings should be confirmed in a larger study in order to identify sub-populations with OSA that may benefit from cannabimimetic pharmacologic therapy.Keywords
This publication has 17 references indexed in Scilit:
- Effects of Continuous Positive Airway Pressure Therapy Withdrawal in Patients with Obstructive Sleep ApneaAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Pharmacology of vagal afferent influences on disordered breathing during sleepRespiratory Physiology & Neurobiology, 2008
- The contribution of VR1 and CB1 receptors and the role of the afferent vagal pathway in modelling of cardio-respiratory effects of anandamide in ratsLife Sciences, 2007
- Functional Role for Cannabinoids in Respiratory Stability During SleepSleep, 2002
- Hypoglossal nerve response to 5-HT3 drugs injected into the XII nucleus and vena cava in the rat.Sleep, 2001
- Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptorsNeuropharmacology, 1999
- Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory actionTrends in Neurosciences, 1998
- Anandamide, an Endogenous Cannabinoid Receptor Ligand, Also Interacts with 5-Hydroxytryptamine (5-HT) Receptor.Biological & Pharmaceutical Bulletin, 1998
- Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neuronsJournal of Neurophysiology, 1995
- EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association.1992